{"id":396496,"date":"2020-12-09T09:32:21","date_gmt":"2020-12-09T14:32:21","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=396496"},"modified":"2020-12-09T09:32:21","modified_gmt":"2020-12-09T14:32:21","slug":"shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\/","title":{"rendered":"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.\u2013 ICPT"},"content":{"rendered":"<div class=\"mw_release\">\n<p>NEW YORK, Dec.  09, 2020  (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) from September 28, 2019 through October 7, 2020, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for Intercept Pharmaceuticals, Inc. investors under the federal securities laws.<\/p>\n<p>To join the class action, go <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6TXznkzbD-aPuVGPafZcZ0_uOQvQPpLdm5hJi6VswEv5-NV7QFbZinsoTVoFgNTe0AWRhpTOaB92g1bqmG6TX2Az53hITbUGkjd6RGyxTOntwCjvjD6yavq17I-oDw0MGZqRjPd0JT2WFoTMbsVe5A==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">here<\/a> or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=uQKJAWQ6_KdbMy7AQ8nuxusZX85KOcmdmi7ctwn2fQgd3i4C9lIIP5cl77PbwtwnV7ZS2tX3RtyOhAC9u3uTV6dRVZi20DPSlqZETq7fdZE=\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">info@pawarlawgroup.com<\/a>\u00a0for information on the class action.<\/p>\n<p>According to the lawsuit, defendants made false and\/or misleading statements and\/or failed to disclose that: (1) defendants downplayed the true scope and severity of safety concerns associated with Ocaliva\u2019s\u00a0(obeticholic acid (\u201cOCA\u201d))\u00a0use in treating primary biliary cholangitis; (2) the foregoing increased the likelihood of an FDA investigation into\u00a0Ocaliva\u2019s development, thereby jeopardizing\u00a0Ocaliva\u2019s continued marketability and the sustainability of its sales; (3) any purported benefits associated with OCA\u2019s efficacy in treating nonalcoholic steatohepatitis (\u201cNASH\u201d) were outweighed by the risks of its use; (4) as a result, the FDA was unlikely to approve Intercept\u2019s New Drug Application for OCA in treating patients with liver fibrosis due to NASH; and (5) as a result of the foregoing, defendants\u2019 positive statements about Intercept\u2019s business, operations, and prospects were materially misleading and\/or lacked a reasonable basis. When the true details entered the market, the lawsuit claims that investors suffered damages.<\/p>\n<p>If you wish to serve as lead plaintiff, you must move the Court no later than <strong>January 4<\/strong><strong>, 202<\/strong><strong>1<\/strong>. A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.<\/p>\n<p>No class has been certified. Until a class is certified, you are not represented by counsel unless you hire one. You may hire counsel of your choice. You may also do nothing at this time and be an absent member of the class. Your ability to share in any future recovery is not dependent upon being a lead plaintiff.<\/p>\n<p>Pawar Law Group represents investors from around the world. Attorney advertising. Prior results do not guarantee or predict a similar outcome with respect to any future matter.<br \/>&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;&#8212;-<\/p>\n<p>Contact:\u00a0\u00a0<br \/>Vik Pawar, Esq.\u00a0\u00a0<br \/>Pawar Law Group\u00a0\u00a0<br \/>20 Vesey Street, Suite 1410\u00a0\u00a0<br \/>New York, NY 10007\u00a0\u00a0<br \/>Tel: (917) 261-2277\u00a0\u00a0<br \/>Fax: (212) 571-0938\u00a0\u00a0<br \/>info@pawarlawgroup.com\u00a0\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODc5NSMzODYyMDE1IzIwODMxNDk=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/8aeb0224-12f7-468b-bf5b-4bc20c95960d\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) from September 28, 2019 through October 7, 2020, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for Intercept Pharmaceuticals, Inc. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0info@pawarlawgroup.com\u00a0for information on the class action. According to the lawsuit, defendants made false and\/or misleading statements and\/or failed to disclose that: (1) defendants downplayed the true scope and severity of safety concerns associated with Ocaliva\u2019s\u00a0(obeticholic acid (\u201cOCA\u201d))\u00a0use in treating primary biliary cholangitis; (2) &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.\u2013 ICPT&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-396496","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.\u2013 ICPT - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.\u2013 ICPT - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) from September 28, 2019 through October 7, 2020, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for Intercept Pharmaceuticals, Inc. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0info@pawarlawgroup.com\u00a0for information on the class action. According to the lawsuit, defendants made false and\/or misleading statements and\/or failed to disclose that: (1) defendants downplayed the true scope and severity of safety concerns associated with Ocaliva\u2019s\u00a0(obeticholic acid (\u201cOCA\u201d))\u00a0use in treating primary biliary cholangitis; (2) &hellip; Continue reading &quot;SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.\u2013 ICPT&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-09T14:32:21+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODc5NSMzODYyMDE1IzIwODMxNDk=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.\u2013 ICPT\",\"datePublished\":\"2020-12-09T14:32:21+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\\\/\"},\"wordCount\":391,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5ODc5NSMzODYyMDE1IzIwODMxNDk=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\\\/\",\"name\":\"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.\u2013 ICPT - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5ODc5NSMzODYyMDE1IzIwODMxNDk=\",\"datePublished\":\"2020-12-09T14:32:21+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5ODc5NSMzODYyMDE1IzIwODMxNDk=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA5ODc5NSMzODYyMDE1IzIwODMxNDk=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.\u2013 ICPT\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.\u2013 ICPT - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\/","og_locale":"en_US","og_type":"article","og_title":"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.\u2013 ICPT - Market Newsdesk","og_description":"NEW YORK, Dec. 09, 2020 (GLOBE NEWSWIRE) &#8212; Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Intercept Pharmaceuticals, Inc. (NASDAQ: ICPT) from September 28, 2019 through October 7, 2020, inclusive (the \u201cClass Period\u201d). The lawsuit seeks to recover damages for Intercept Pharmaceuticals, Inc. investors under the federal securities laws. To join the class action, go here or call Vik Pawar, Esq. toll-free at 888-589-9804 or email\u00a0info@pawarlawgroup.com\u00a0for information on the class action. According to the lawsuit, defendants made false and\/or misleading statements and\/or failed to disclose that: (1) defendants downplayed the true scope and severity of safety concerns associated with Ocaliva\u2019s\u00a0(obeticholic acid (\u201cOCA\u201d))\u00a0use in treating primary biliary cholangitis; (2) &hellip; Continue reading \"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.\u2013 ICPT\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-09T14:32:21+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODc5NSMzODYyMDE1IzIwODMxNDk=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.\u2013 ICPT","datePublished":"2020-12-09T14:32:21+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\/"},"wordCount":391,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODc5NSMzODYyMDE1IzIwODMxNDk=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\/","name":"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.\u2013 ICPT - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODc5NSMzODYyMDE1IzIwODMxNDk=","datePublished":"2020-12-09T14:32:21+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODc5NSMzODYyMDE1IzIwODMxNDk=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA5ODc5NSMzODYyMDE1IzIwODMxNDk="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholder-deadline-pawar-law-group-announces-a-securities-class-action-lawsuit-against-intercept-pharmaceuticals-inc-icpt\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"SHAREHOLDER DEADLINE: Pawar Law Group Announces a Securities Class Action Lawsuit Against Intercept Pharmaceuticals, Inc.\u2013 ICPT"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/396496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=396496"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/396496\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=396496"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=396496"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=396496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}